---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-27T14:22:07.249152'
end_time: '2025-12-27T14:30:02.773825'
duration_seconds: 475.52
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: MED13L
  gene_symbol: MED13L
  uniprot_accession: Q71F56
  protein_description: 'RecName: Full=Mediator of RNA polymerase II transcription
    subunit 13-like; AltName: Full=Mediator complex subunit 13-like; AltName: Full=Thyroid
    hormone receptor-associated protein 2; AltName: Full=Thyroid hormone receptor-associated
    protein complex 240 kDa component-like;'
  gene_info: Name=MED13L; Synonyms=KIAA1025, PROSIT240, THRAP2, TRAP240L;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the Mediator complex subunit 13 family.
  protein_domains: Med13_C. (IPR009401); Mediator_complx_sub13. (IPR051139); Mediator_Med13_N.
    (IPR021643); MID_MedPIWI. (IPR041285); Med13_C (PF06333)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 22
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q71F56
- **Protein Description:** RecName: Full=Mediator of RNA polymerase II transcription subunit 13-like; AltName: Full=Mediator complex subunit 13-like; AltName: Full=Thyroid hormone receptor-associated protein 2; AltName: Full=Thyroid hormone receptor-associated protein complex 240 kDa component-like;
- **Gene Information:** Name=MED13L; Synonyms=KIAA1025, PROSIT240, THRAP2, TRAP240L;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the Mediator complex subunit 13 family.
- **Key Domains:** Med13_C. (IPR009401); Mediator_complx_sub13. (IPR051139); Mediator_Med13_N. (IPR021643); MID_MedPIWI. (IPR041285); Med13_C (PF06333)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "MED13L" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'MED13L' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **MED13L** (gene ID: MED13L, UniProt: Q71F56) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q71F56
- **Protein Description:** RecName: Full=Mediator of RNA polymerase II transcription subunit 13-like; AltName: Full=Mediator complex subunit 13-like; AltName: Full=Thyroid hormone receptor-associated protein 2; AltName: Full=Thyroid hormone receptor-associated protein complex 240 kDa component-like;
- **Gene Information:** Name=MED13L; Synonyms=KIAA1025, PROSIT240, THRAP2, TRAP240L;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the Mediator complex subunit 13 family.
- **Key Domains:** Med13_C. (IPR009401); Mediator_complx_sub13. (IPR051139); Mediator_Med13_N. (IPR021643); MID_MedPIWI. (IPR041285); Med13_C (PF06333)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "MED13L" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'MED13L' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **MED13L** (gene ID: MED13L, UniProt: Q71F56) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan and verification
- Identity check: The target is human MED13L, UniProt Q71F56, also known as THRAP2/TRAP240L/KIAA1025, a Mediator complex subunit 13 family member. The organism is Homo sapiens, and MED13L is a paralog of MED13. This matches the user-provided UniProt identity and literature below (siavrienė 2023; Campbell/Bain/Doyle GeneReviews excerpt, 2025) (siavriene2023molecularandfunctional pages 9-10, campbell2025med13lsyndromea pages 12-15).

| Category | Key facts | Evidence/source (DOI/URL, year) |
|---|---|---|
| Identity / verification | Gene: MED13L (aliases KIAA1025, THRAP2, TRAP240L); organism: Homo sapiens; UniProt accession Q71F56 confirmed in clinical/genetic studies. | Siavrienė et al., Medicina 2023; https://doi.org/10.3390/medicina59071225 (siavriene2023molecularandfunctional pages 9-10) |
| Domains | Contains Ago-like domain architecture (Med13_N, PAZ, MID/MedPIWI, Med13_C), large intrinsically disordered regions (IDRs); MedPIWI/MID core implicated in regulatory conformational switching. | Chen et al., bioRxiv 2024; https://doi.org/10.1101/2024.07.01.601608 (chen2024structuralbasisof pages 27-34), Siavrienė et al., Medicina 2023 (siavriene2023molecularandfunctional pages 9-10) |
| Complex membership & role | Member of Mediator CDK8 kinase module (CKM) paralog set MED12/12L, MED13/13L, CDK8/19, cyclin C; MED13L (paralog of MED13) tethers CKM to core Mediator and can modulate Pol II access. | Siavrienė et al., Medicina 2023; Chen et al., bioRxiv 2024 (siavriene2023molecularandfunctional pages 9-10, chen2024structuralbasisof pages 27-34) |
| Structural insights (2024 cryo-EM / XL-MS) | Cryo-EM + XL-MS place CKM docked on cMED Hook; MED13/13L IDRc crosslinks overlap Pol II/MED26-binding sites suggesting IDR occlusion of cMED–Pol II interaction; zinc-binding sites observed in MED13 (structural inference). | Chen et al., bioRxiv (preprint) Jul 2024; https://doi.org/10.1101/2024.07.01.601608 (chen2024structuralbasisof pages 27-34, chen2024structuralbasisof pages 39-42) |
| Localization | Predominantly nuclear (Mediator function) with reported neuronal synapse localization and roles in cortical neurons. | Siavrienė et al., Medicina 2023; Hamada et al., J Neurochemistry 2023; https://doi.org/10.1111/jnc.15783 (siavriene2023molecularandfunctional pages 9-10, hamada2023med13landits pages 18-19) |
| Pathways | Influences transcription programs including Wnt/FGF signaling and Rb/E2F cell-cycle networks; links to Notch/Wnt-β-catenin reported in mediator/CKM literature and neurodevelopmental studies. | Siavrienė et al., Medicina 2023 (Wnt/FGF); Chen et al., bioRxiv 2024 (Mediator/CKM mechanisms) (siavriene2023molecularandfunctional pages 9-10, chen2024structuralbasisof pages 27-34) |
| Regulation | MED13L/CKM dynamics affect cyclin C localization and stress responses (cyclin C nuclear release → mitochondrial effects); MED13-family IDR exposure controls CKM dissociation; proteolytic regulation of Med13 family reported (degron/SCF-type mechanisms in related studies). | Siavrienė et al., Medicina 2023; Chen et al., bioRxiv 2024; GeneReviews excerpt (siavriene2023molecularandfunctional pages 9-10, chen2024structuralbasisof pages 27-34, campbell2025med13lsyndromea pages 12-15) |
| Core functions | Non-enzymatic adaptor/tether within Mediator CKM that modulates Pol II pre-initiation/pausing/elongation decisions; required for normal cortical neurogenesis and dendritic development (neuronal differentiation/morphology phenotypes). | Hamada et al., J Neurochemistry 2023; Siavrienė et al., Medicina 2023 (hamada2023med13landits pages 18-19, siavriene2023molecularandfunctional pages 9-10) |
| Disease relevance | Heterozygous loss-of-function (haploinsufficiency) and pathogenic missense MED13L variants cause MED13L syndrome (developmental delay/intellectual disability ± congenital heart defects); de novo variants common; parental germline/somatic mosaicism reported. | Siavrienė et al., Medicina 2023; Bessenyei et al., Cold Spring Harbor Mol Case Stud 2022; literature compendia (siavriene2023molecularandfunctional pages 9-10, clevenger2025diseaseconceptmodel pages 63-64) |
| Phenotype frequencies (2023 data) | In a 2023 cohort: neurodevelopmental features nearly universal (ID/DD, speech delay); hypotonia and craniofacial/ophthalmologic findings frequent; congenital heart defects reported ~20.8% (cohort-specific). | Siavrienė et al., Medicina 2023; https://doi.org/10.3390/medicina59071225 (siavriene2023molecularandfunctional pages 9-10) |
| Translational landscape | Active patient-advocacy-driven research roadmap (MED13L Foundation SRP 2024) and recommendations for clinical genetic testing and variant interpretation; preclinical models and natural-history efforts prioritized for trial readiness. | Heilmann et al., MED13L Foundation SRP / Therapeutic Adv Rare Dis 2024; GeneReviews excerpt and foundation materials (clevenger2025diseaseconceptmodela pages 63-64, campbell2025med13lsyndromea pages 12-15) |


*Table: Compact summary table of human MED13L (Q71F56) covering identity, domains, Mediator/CKM role, structural and functional insights, regulation, disease links, phenotype frequencies, and translational resources with primary 2023–2024 sources for rapid reference.*

Comprehensive research report

1) Key concepts and definitions (current understanding)
- Definition and complex membership: MED13L encodes Mediator of RNA polymerase II transcription subunit 13-like, a non-enzymatic subunit of the Mediator complex’s cyclin-dependent kinase module (CKM). The vertebrate CKM comprises CDK8/19, cyclin C (CCNC), MED12/MED12L, and MED13/MED13L. MED13L is paralogous to MED13 and functions as a tether that links the CKM to the core Mediator (cMED), modulating Pol II engagement and transcriptional programs (Jun 2023; Jul 2024 preprint) (siavriene2023molecularandfunctional pages 9-10, chen2024structuralbasisof pages 27-34, chen2024structuralbasisof pages 39-42). URL: https://doi.org/10.3390/medicina59071225 (Jun 2023); https://doi.org/10.1101/2024.07.01.601608 (posted Jul 3, 2024).
- Domain architecture: MED13/13L exhibits an Argonaute-like fold with N/PAZ/MID(=MedPIWI)/PIWI elements and large intrinsically disordered regions (IDRs). Discrete Med13_N, MID/MedPIWI, and Med13_C modules are recognized; the MedPIWI/MID core is implicated in CKM regulatory switching (Jul 2024 preprint; Jun 2023) (chen2024structuralbasisof pages 27-34, siavriene2023molecularandfunctional pages 9-10). URL: https://doi.org/10.1101/2024.07.01.601608; https://doi.org/10.3390/medicina59071225.
- Cellular localization and expression: MED13L is broadly expressed across human tissues, with notable expression in brain regions and fibroblasts; it localizes primarily to the nucleus consistent with Mediator function, with additional reports of synaptic localization in neurons (Jun 2023; Feb 2023) (siavriene2023molecularandfunctional pages 9-10, hamada2023med13landits pages 18-19). URL: https://doi.org/10.3390/medicina59071225; https://doi.org/10.1111/jnc.15783.
- Primary biochemical role: MED13L is an adaptor/tether within the CKM that influences the Mediator–Pol II interface and promoter-proximal events; it does not catalyze enzymatic reactions. Through CKM placement, MED13L helps control access of Pol II and cofactors (e.g., MED26), thereby affecting initiation and pause-release programs (Jul 2024 preprint) (chen2024structuralbasisof pages 27-34, chen2024structuralbasisof pages 39-42). URL: https://doi.org/10.1101/2024.07.01.601608.

2) Recent developments and latest research (priority 2023–2024)
- Cryo-EM/XL-MS placement of MED13/MED13L within CKM and on cMED: Human CKM docked onto the cMED Hook was resolved by cryo-EM; crosslinks indicate that MED13/13L C-terminal IDRs contact the cMED Hook and overlap the Pol II/MED26 binding surfaces on cMED. This supports a mechanism where MED13/13L IDRs can occlude cMED–Pol II/ MED26 interactions, gating cMED–PIC assembly; dissociation/repositioning of MED13/13L facilitates Pol II engagement. Additional structural observations include putative zinc-binding features in MED13 and an active CDK8 T-loop conformation within the docked CKM (bioRxiv, posted Jul 3, 2024) (chen2024structuralbasisof pages 27-34, chen2024structuralbasisof pages 39-42). URL: https://doi.org/10.1101/2024.07.01.601608.
- Neuronal development: In vivo studies show MED13L is required for dendritic development of cortical excitatory neurons; disease-associated variants impact subcellular distribution/stability and reduce dendrite number/length or spine maturation. Knockdown impairs dendritic growth, rescued by RNAi-resistant MED13L (Journal of Neurochemistry, Feb 2023) (hamada2023med13landits pages 18-19). URL: https://doi.org/10.1111/jnc.15783.
- Human genetics—novel deletions and functional validation: A 2023 study characterized a novel intragenic 12q24.21 deletion (exons 3–10) producing a frameshift and predicted truncation that disrupts Med13_N and removes MedPIWI/Med13_C, consistent with haploinsufficiency. Patient fibroblasts had markedly reduced MED13L protein; CRISPR-Cas9 knockout in control fibroblasts decreased viability, and expression analyses indicated perturbation of Wnt/FGF signaling and Rb/E2F-related programs (Medicina, Jun 2023) (siavriene2023molecularandfunctional pages 9-10, siavriene2023molecularandfunctional pages 13-14). URL: https://doi.org/10.3390/medicina59071225.
- Translational roadmap: The MED13L Foundation Strategic Research Plan (Therapeutic Advances in Rare Disease, 2024) synthesizes literature and outlines clinical trial readiness tools, natural history efforts, and priorities toward therapies for MED13L syndrome (2024) (clevenger2025diseaseconceptmodela pages 63-64). URL: https://doi.org/10.1177/26330040241290252.

3) Current applications and real-world implementations
- Clinical diagnostics: Exome/genome sequencing (including CNV analysis) and RNA studies to detect intragenic deletions, truncating variants, and missense changes are standard approaches for suspected MED13L syndrome. Family testing for mosaicism is recommended due to documented germline mosaicism leading to recurrence risk (case evidence 2022) (campbell2025med13lsyndromea pages 12-15, yi2020reportofa pages 10-10). URL: https://doi.org/10.1101/mcs.a006124 (Oct 2022); https://doi.org/10.1186/s13052-020-00847-y (Jul 2020).
- Functional cell assays: Western blot quantification of MED13L, CRISPR-mediated knockdown/knockout in patient/control fibroblasts, and transcriptome analyses to confirm haploinsufficiency consequences and pathway dysregulation (Jun 2023) (siavriene2023molecularandfunctional pages 9-10). URL: https://doi.org/10.3390/medicina59071225.
- Research resources and advocacy: The 2024 MED13L Foundation plan provides a community-facing framework to coordinate natural history, biomarker development, and preclinical models for therapy development (2024) (clevenger2025diseaseconceptmodela pages 63-64). URL: https://doi.org/10.1177/26330040241290252.

4) Expert opinions and analysis from authoritative sources
- GeneReviews-style synthesis (Campbell, Bain, Doyle excerpt, 2025): MED13L and MED13 act as the protein tether linking CKM to Mediator. Pathogenic variants cause transcriptional defects and may perturb cyclin C localization; most disease-causing variants are de novo and consistent with haploinsufficiency, though severe missense alleles can produce more pronounced phenotypes. Recommendation: consider parental mosaicism in recurrence risk (2025) (campbell2025med13lsyndromea pages 12-15). 
- Structural analysis (2024 preprint): The CKM–cMED arrangement rationalizes how MED13/13L IDRs regulate cMED’s ability to bind Pol II/MED26 and to reposition CKM to act on pausing factors, aligning molecular placement with control of initiation/pausing/elongation transitions (posted Jul 2024) (chen2024structuralbasisof pages 27-34, chen2024structuralbasisof pages 39-42). URL: https://doi.org/10.1101/2024.07.01.601608.
- Neurobiology (2023): MED13L is required cell-autonomously in cortical neurons for dendritic growth/spine maturation, providing a mechanistic link to neurodevelopmental phenotypes in patients (Feb 2023) (hamada2023med13landits pages 18-19). URL: https://doi.org/10.1111/jnc.15783.

5) Relevant statistics and data from recent studies
- Frequency of clinical features (2023 cohort): Near-universal developmental delay/intellectual disability and speech impairment; hypotonia and dysmorphic/ophthalmologic findings frequent; congenital heart defects in about 20.8% (15/72) in the literature summarized within the 2023 report (Jun 2023) (siavriene2023molecularandfunctional pages 9-10). URL: https://doi.org/10.3390/medicina59071225.
- Variant spectrum: Heterozygous loss-of-function (nonsense, frameshift, canonical splice-site), intragenic deletions, and missense variants; de novo events predominate; documented parental germline mosaicism (2022 case study) (yi2020reportofa pages 10-10). URL: https://doi.org/10.1101/mcs.a006124 (Oct 2022).

Mechanistic integration
- Role in transcription and pathways: As a CKM tether, MED13L’s IDRs can restrict or allow cMED interaction with Pol II/MED26, shaping promoter engagement and pause control. Human cellular models indicate MED13L loss alters Wnt and FGF pathways and Rb/E2F cell-cycle modules, consistent with CKM’s broad transcriptional regulatory scope (2023–2024) (chen2024structuralbasisof pages 27-34, chen2024structuralbasisof pages 39-42, siavriene2023molecularandfunctional pages 9-10).
- Regulation and stress responses: CKM components exhibit stress-responsive dynamics. Prior work implicates SCF-dependent proteolysis of Med13 family members and CKM-driven cyclin C relocalization with mitochondrial effects; patient-focused reviews note cyclin C mislocalization in MED13L pathogenic settings (2018; 2025 excerpt) (campbell2025med13lsyndromea pages 12-15). While specific human E3 ligase targeting of MED13L was not detailed in the provided 2023–2024 evidence, the conserved paradigm supports regulated CKM composition and localization.
- Neurodevelopment and heart development: Mouse and human cellular data support key roles of MED13L in neuronal differentiation, dendritic arborization, and brain development; human clinical cohorts consistently show neurodevelopmental phenotypes, and congenital heart defects are present in a subset (~20% in one 2023 dataset), in line with Mediator’s roles in developmental transcription programs (Feb 2023; Jun 2023) (hamada2023med13landits pages 18-19, siavriene2023molecularandfunctional pages 9-10).

Clinical implications and translational directions (2024 focus)
- Diagnostic recommendations: Employ exome/genome sequencing with CNV detection; consider RNA analysis for splice-impacting variants; test parents for mosaicism to refine recurrence risk (2022–2025) (yi2020reportofa pages 10-10, campbell2025med13lsyndromea pages 12-15).
- Therapeutic outlook: The 2024 MED13L Foundation plan outlines priorities including natural history studies, standardized outcome measures, and preclinical model development to enable future trials (2024) (clevenger2025diseaseconceptmodela pages 63-64). URL: https://doi.org/10.1177/26330040241290252.

Conclusions
MED13L (Q71F56) is a human Mediator CKM tether with Ago-like domain architecture whose IDRs regulate cMED–Pol II engagement and promoter-proximal control. Recent structural work provides a mechanistic basis for MED13/13L gating of Pol II/MED26 access, while 2023 neuronal studies show MED13L’s necessity for dendritogenesis. Human genetics consolidates MED13L haploinsufficiency syndrome with predominantly de novo variants, documented mosaicism, and frequent neurodevelopmental features with variable cardiac involvement. Translational frameworks are being established to advance clinical research and therapeutic readiness (chen2024structuralbasisof pages 27-34, chen2024structuralbasisof pages 39-42, hamada2023med13landits pages 18-19, siavriene2023molecularandfunctional pages 9-10, yi2020reportofa pages 10-10, clevenger2025diseaseconceptmodela pages 63-64, campbell2025med13lsyndromea pages 12-15).

References

1. (siavriene2023molecularandfunctional pages 9-10): Evelina Siavrienė, Gunda Petraitytė, Violeta Mikštienė, Živilė Maldžienė, Aušra Sasnauskienė, Vilmantė Žitkutė, Laima Ambrozaitytė, Tautvydas Rančelis, Algirdas Utkus, Vaidutis Kučinskas, and Eglė Preikšaitienė. Molecular and functional characterisation of a novel intragenic 12q24.21 deletion resulting in med13l haploinsufficiency syndrome. Medicina, 59:1225, Jun 2023. URL: https://doi.org/10.3390/medicina59071225, doi:10.3390/medicina59071225. This article has 8 citations and is from a poor quality or predatory journal.

2. (campbell2025med13lsyndromea pages 12-15): AN Campbell, J Bain, and SJ Doyle. Med13l syndrome. Unknown journal, 2025.

3. (chen2024structuralbasisof pages 27-34): Shin-Fu Chen, Ti-Chun Chao, Hee Jong Kim, Hui-Chi Tang, Subash Khadka, Tao Li, Dung-Fang Lee, Kenji Murakami, Thomas G. Boyer, and Kuang-Lei Tsai. Structural basis of the human transcriptional mediator complex modulated by its dissociable kinase module. bioRxiv, Jul 2024. URL: https://doi.org/10.1101/2024.07.01.601608, doi:10.1101/2024.07.01.601608. This article has 1 citations and is from a poor quality or predatory journal.

4. (chen2024structuralbasisof pages 39-42): Shin-Fu Chen, Ti-Chun Chao, Hee Jong Kim, Hui-Chi Tang, Subash Khadka, Tao Li, Dung-Fang Lee, Kenji Murakami, Thomas G. Boyer, and Kuang-Lei Tsai. Structural basis of the human transcriptional mediator complex modulated by its dissociable kinase module. bioRxiv, Jul 2024. URL: https://doi.org/10.1101/2024.07.01.601608, doi:10.1101/2024.07.01.601608. This article has 1 citations and is from a poor quality or predatory journal.

5. (hamada2023med13landits pages 18-19): Nanako Hamada, Ikuko Iwamoto, and Koh‐ichi Nagata. <scp>med13l</scp> and its disease‐associated variants influence the dendritic development of cerebral cortical neurons in the mammalian brain. Journal of Neurochemistry, 165:334-347, Feb 2023. URL: https://doi.org/10.1111/jnc.15783, doi:10.1111/jnc.15783. This article has 12 citations and is from a domain leading peer-reviewed journal.

6. (clevenger2025diseaseconceptmodel pages 63-64): KM Clevenger. Disease concept model for med13l syndrome. Unknown journal, 2025.

7. (clevenger2025diseaseconceptmodela pages 63-64): KM Clevenger. Disease concept model for med13l syndrome. Unknown journal, 2025.

8. (siavriene2023molecularandfunctional pages 13-14): Evelina Siavrienė, Gunda Petraitytė, Violeta Mikštienė, Živilė Maldžienė, Aušra Sasnauskienė, Vilmantė Žitkutė, Laima Ambrozaitytė, Tautvydas Rančelis, Algirdas Utkus, Vaidutis Kučinskas, and Eglė Preikšaitienė. Molecular and functional characterisation of a novel intragenic 12q24.21 deletion resulting in med13l haploinsufficiency syndrome. Medicina, 59:1225, Jun 2023. URL: https://doi.org/10.3390/medicina59071225, doi:10.3390/medicina59071225. This article has 8 citations and is from a poor quality or predatory journal.

9. (yi2020reportofa pages 10-10): Zhi Yi, Ying Zhang, Zhenfeng Song, Hong Pan, Chengqing Yang, Fei Li, Jiao Xue, and Zhenghai Qu. Report of a de novo c.2605c > t (p.pro869ser) change in the med13l gene and review of the literature for med13l-related intellectual disability. Italian Journal of Pediatrics, Jul 2020. URL: https://doi.org/10.1186/s13052-020-00847-y, doi:10.1186/s13052-020-00847-y. This article has 16 citations and is from a peer-reviewed journal.

## Citations

1. siavriene2023molecularandfunctional pages 9-10
2. chen2024structuralbasisof pages 27-34
3. clevenger2025diseaseconceptmodela pages 63-64
4. yi2020reportofa pages 10-10
5. chen2024structuralbasisof pages 39-42
6. clevenger2025diseaseconceptmodel pages 63-64
7. siavriene2023molecularandfunctional pages 13-14
8. https://doi.org/10.3390/medicina59071225
9. https://doi.org/10.1101/2024.07.01.601608
10. https://doi.org/10.1111/jnc.15783
11. https://doi.org/10.1101/2024.07.01.601608;
12. https://doi.org/10.3390/medicina59071225.
13. https://doi.org/10.3390/medicina59071225;
14. https://doi.org/10.1111/jnc.15783.
15. https://doi.org/10.1101/2024.07.01.601608.
16. https://doi.org/10.1177/26330040241290252.
17. https://doi.org/10.1101/mcs.a006124
18. https://doi.org/10.1186/s13052-020-00847-y
19. https://doi.org/10.3390/medicina59071225,
20. https://doi.org/10.1101/2024.07.01.601608,
21. https://doi.org/10.1111/jnc.15783,
22. https://doi.org/10.1186/s13052-020-00847-y,